Latest News

Instem Acquires PDS Life Sciences to Help Clients Bring Life Enhancing Products to Market Faster and More Efficiently

Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support

PHILADELPHIA, PA – (BUSINESS WIRE) – September 1, 2021 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that it has acquired PDS Life Sciences (PDS) as part of its mission to enable clients to bring their life enhancing products to market faster. This further consolidation by Instem of key application areas will help customers streamline and accelerate their research and development processes, while enabling clients to access data from across the R&D continuum, increasing the power of current and future in silico modelling and prediction solutions.

Instem to Release Next Edition of its Leading Computational Toxicology Software Suite

July 29, 2021 - Powerful New In Silico Models and First-to-Market Software Capabilities to Deliver Further Efficiencies and Increased Regulatory Compliance

Instem Acquires Market Leader d-wise to Further Accelerate Life Science Development

March 22, 2021 - Instem’s Acquisition of Leading Clinical Trial Technology and Consulting Provider d-wise Represents Substantial Advancement of its Mission

Instem Announces Acquisition of The Edge; Extends Reach within Discovery R&D

March 1, 2021 - Instem’s Acquisition of Discovery Technology Solutions Provider, The Edge, Represents Another Advancement of its Mission in the Life Sciences

Instem Reports Another Year of High Growth for In Silico Solutions

January 27, 2021 - High Demand for Target Safety Assessment Services and Computational Toxicology Solutions Continues Throughout Discovery and Nonclinical

View all news



50th JEMS Annual Meeting

November 1 - 2, 2021

Hybrid Event, Yokosuka, Japan

Visit Conference Site

ACT Annual Meeting 2021

November 14 - 17, 2021

Virtual Conference

Assessing abuse liability using read-across and structural alerts
Development of a Structure-Activity Relationship Profiler to Predict Mechanism-Based Inhibition of a Metabolite on CYP Enzymes
Using Metabolically Similar Analogs in Read-Across to Establish Dialkyl-N-Nitrosamine Potency

Visit ACT Events Page

Visit Conference Site


View all events